If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
Exploring the companies and themes that make up this emerging and exciting new sector
MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
The Company expects to have ibogaine manufactured and in use for research by Q4.
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
ATAI announces closing its Series D financing round, raising $157 million.
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
First-of-its-kind trial finds psychedelic microdosing is equal to placebo
A first of its kind "self-blinded" trial testing the effect of psychedelic microdosing has found the anecdotally popular practice may be an example of a strong placebo effect.
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
Novamind reports rising revenues and cash on hand of CAD$10 million.
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Mydecine exports dried psilocybin mushrooms from Jamaica to Canada.
What Field Trip’s Huge Financing Tells Investors
Field Trip Health just announced the 3rd largest financing by a psychedelics public company: a CAD$82.875 million bought deal. Here's what it means for investors.
Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering
With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
Optimi Health Corp. Completes Oversubscribed $20.7 Million Initial Public Offering, and Announces Listing on the CSE
Optimi Health has commenced public trading (symbol "OPTI"). The Company raised CAD$20.7 million for its IPO financing.
Red Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil
TRIP gains access to the huge Brazilian market for its psilocybin truffles.
PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange
PsyBio has commenced trading. Its focus is on drug development for the Mental Health Crisis.